Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Covington
McKinsey
Chubb
Citi
UBS
Colorcon
Fish and Richardson
Queensland Health
Harvard Business School

Generated: October 24, 2017

DrugPatentWatch Database Preview

NIASPAN TITRATION STARTER PACK Drug Profile

« Back to Dashboard

What is the patent landscape for Niaspan Titration Starter Pack, and when can generic versions of Niaspan Titration Starter Pack launch?

Niaspan Titration Starter Pack is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-four patent family members in ten countries.

The generic ingredient in NIASPAN TITRATION STARTER PACK is niacin. There are fourteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the niacin profile page.

Summary for Tradename: NIASPAN TITRATION STARTER PACK

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list9
Bulk Api Vendors: see list107
Clinical Trials: see list1,375
Patent Applications: see list9,244
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NIASPAN TITRATION STARTER PACK at DailyMed

Pharmacology for Tradename: NIASPAN TITRATION STARTER PACK

Ingredient-typeNicotinic Acids
Drug ClassNicotinic Acid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NIASPAN TITRATION STARTER PACK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NIASPAN TITRATION STARTER PACK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night► Subscribe
7,998,506Nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia► Subscribe
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia► Subscribe
7,011,848Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles► Subscribe
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NIASPAN TITRATION STARTER PACK

Country Document Number Estimated Expiration
Canada2283159► Subscribe
Finland119910► Subscribe
European Patent Office0966284► Subscribe
Austria289197► Subscribe
Norway994275► Subscribe
Australia6454598► Subscribe
Canada2283322► Subscribe
Brazil9815457► Subscribe
Canada2591710► Subscribe
Canada2574987► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Mallinckrodt
Citi
Teva
Fish and Richardson
Express Scripts
QuintilesIMS
US Department of Justice
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot